Advertisement

Topics

Chembio Diagnostics Company Profile

09:48 EDT 18th June 2018 | BioPortfolio

Chembio Diagnostic Systems, Inc. is a US company serving the increasing global demand for rapid tests needed for the effective prevention and treatment of infectious diseases, and other conditions. Chembio's focus is on developing, manufacturing and marketing tests for the rapid, simple and cost-effective detection of HIV, Tuberculosis (human and veterinary), and certain other Neglected Diseases. Chembio has a proven commitment toward ensuring sustainable supplies of high quality rapid tests to those who need them by using innovative, socially responsible strategies.


News Articles [372 Associated News Articles listed on BioPortfolio]

Chembio Diagnostics nets $11.2mm via FOPO

Chembio Diagnostics Inc. (point-of-care tests for infectious diseases) netted $11.2mm through the public offering of 1.78mm common shares at $6.75 each. The company will use the funds for development ...

Chembio enters $2.9M deal with AstraZeneca on POC test development

Biopharmaceutical company AstraZeneca agreed to provide up to $2.9 million in funding to Chembio Diagnostics to support the d -More- 

Chembio Diagnostics Announces Agreement with Bio-Manguinhos to Commercialize Point-of-Care Tests for Dengue, Zika and Chikungunya in Brazil

Chembio Diagnostics (Nasdaq:CEMI), a leader in point-of-care (“POC”) diagnostic tests for infectious diseases, today announced the signing of a long-term agreement with Bio-Manguinhos to c...

Chembio, LumiraDx to develop Dx tests for global health threats

Chembio Diagnostics and LumiraDx entered into a collaborative agreement that will involve developing point-of-care diagnostic -More- 

Chembio announces pricing of $11.2M public offering

A public offering of about 1.8 million shares of common stock was priced by Chembio Diagnostics at $6.75 apiece in hopes of r -More- 

Chembio Diagnostics' (CEMI) CEO John Sperzel on Q1 2018 Results - Earnings Call Transcript

Chembio Diagnostics' (CEMI) CEO John Sperzel on Q4 2017 Results - Earnings Call Transcript

Chembio prices $12M follow-on

Drugs and Medications [20 Associated Drugs and Medications listed on BioPortfolio]

Oxygen [A.M. Home Diagnostics Inc. dba Healthline]

Oxygen

Cystografin dilute diatrizoate meglumine injection usp 18% [Bracco Diagnostics Inc.]

CYSTOGRAFIN DILUTE Diatrizoate Meglumine Injection USP 18%

Cystografin diatrizoate meglumine injection usp 30% [Bracco Diagnostics Inc.]

CYSTOGRAFIN Diatrizoate Meglumine Injection USP 30%

Multihance [Bracco Diagnostics Inc]

These highlights do not include all the information needed to use MultiHance safely and effectively. See full prescribing information for MultiHance. MultiHance (gadobenate dimeglumine) injection Init...

Reno-30 diatrizoate meglumine injection usp 30% [Bracco Diagnostics Inc.]

RENO-30 Diatrizoate Meglumine Injection USP 30%

PubMed Articles [195 Associated PubMed Articles listed on BioPortfolio]

Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.

The importance of medical imaging in the diagnosis and monitoring of cancer cannot be overstated. As personalized cancer treatments are gaining popularity, a need for more advanced imaging techniques ...

A PEG-based method for the isolation of urinary exosomes and its application in renal fibrosis diagnostics using cargo miR-29c and miR-21 analysis.

To assess a new and highly specific, but low-cost, easily performed and suitable for large-scale applications method for renal fibrosis (RF) diagnostics.

Nucleic acid diagnostic approaches in parasitology.

Nucleic acid diagnostic technologies are partly replacing traditional microscopy and antigen detection methods in parasitological diagnostics. In particular, the diagnostics of parasitic diarrhea is u...

Is bronchoscopy always justified in diagnosis of haemoptysis?

Fiber-optic bronchoscopy (FOB) is commonly performed in the first line in diagnostic process of haemoptysis. However, lots of evidences suggest that in haemoptysis FOB do not always provide additional...

Molecular allergy diagnostics refines characterization of children sensitized to dog dander.

Sensitization to dog dander is an important risk factor for rhino-conjunctivitis and asthma, but not sufficient for diagnosing dog allergy. Molecular allergy diagnostics offers new opportunities for r...

Clinical Trials [196 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test

This study has been designed to evaluate the performance of the Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 rapid test. The device is intended to qualitatively detect the presence of ...

Clinical Sensitivity of Clearview Rapid Tests in 12-17 y/o Pediatric Population

This study is to establish the clinical sensitivity of the Chembio Diagnostics Systems, Inc. Clearview COMPLETE HIV 1/2 Assay and Clearview HIV 1/2 Stat-Pak Assay (Clearview HIV tests) in ...

Differential Diagnostics of Etiology of Acute Infections

Method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.

Bedside vs. Standard Microbiological Blood Culture Diagnostics - BEMIDIA Study

With a completely bedside blood culture diagnostics system (BACTEC blood culture system in combination with the Accelerate ID/AST System) it is possible to optimize the initial antimicrobi...

MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

The purpose of this study is to assess the performance of the HTLV Blot 2.4 from patients with the following conditions: infected with HTLV and neurological conditions with symptoms simila...

Companies [920 Associated Companies listed on BioPortfolio]

Chembio Diagnostics

Chembio Diagnostic Systems, Inc. is a US company serving the increasing global demand for rapid tests needed for the effective prevention and treatment of infectious diseases, and other conditions. Ch...

Chembio Diagnostic Systems Incorporated

Chembio Diagnostic Systems, Inc., is a U.S. biotechnology company located in Medford, New York. The company discovers, develops, manufactures and markets rapid immunodiagnostic tests. Chembio's rapid ...

Chembio Diagnostic Systems, Inc.

Chembio Diagnostic Systems, Inc. is a US company serving the increasing global demand for rapid tests needed for the effective prevention and treatment of infectious diseases, and other conditions. Ch...

Sekisui Diagnostics

A Sekisui Chemical company since 2011, Sekisui Diagnostics is a leading supplier of high quality products to diagnostic manufacturers, clinical laboratories and physician offices ...

Innotrac Diagnostics Oy

Founded 1995Located in Turku, FinlandInnotrac Diagnostics provides health care professionals with a comprehensive immunoassay platform and test portfolio for rapid and high quality results in cardiac ...

More Information about "Chembio Diagnostics" on BioPortfolio

We have published hundreds of Chembio Diagnostics news stories on BioPortfolio along with dozens of Chembio Diagnostics Clinical Trials and PubMed Articles about Chembio Diagnostics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chembio Diagnostics Companies in our database. You can also find out about relevant Chembio Diagnostics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Corporate Database Quicklinks



Searches Linking to this Company Record